Martha French


Vice President of Regulatory Affairs

Martha French

Martha French joined Bellicum in 2011 with over 25 years combined experience in biomedical research and regulatory affairs. As Director of Regulatory Affairs at InGeneron Inc., she was responsible for the management of European and US regulatory activities for medical devices that prepare autologous regenerative cell therapies at point of care. At Introgen Therapeutics, Martha led US and European pre-market regulatory activities for three novel biologic products. She was responsible for the filing of the first gene therapy Biologics License Application (BLA) to the FDA and filed two gene therapy Marketing Authorization Applications (MAA) to the EMA. At Valentis, Inc. (formerly Gene Medicine Inc.), Ms. French led the Analytical Sciences core teams in support of the company’s cardiovascular, oncology and PEG protein programs. With long tenure at Lark Technologies, as Vice President of Operations, she managed the DNA sequencing, library screening, restriction enzyme mapping and PCR services. Ms. French graduated from Carroll University with a Bachelor of Science in Biology, taught Regulatory Affairs for the 2008 Human Gene Therapy course at the University of Texas Graduate School of Biomedical Sciences.